Are the Shorts Wrong About Dendreon?

Dave Williamson
Dave Williamson
Sep 1, 2012 at 12:00AM

In this video entry, David and Austin focus on Dendreon, which has attracted shorts as the company continues to struggle launching prostate-cancer vaccine Provenge. Is it time to invest in this cutting-edge company on the cheap, or is the high short interest a sign of further troubles ahead? Watch and find out.

Many investors are attracted to Dendreon and biotechs like it since they hold the allure of substantial short-term gains. But there's more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.